Overview

AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation

Status:
Not yet recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle cream in the treatment of moderate acne vulagris with risk of acne-induced post inflammatory hyperpigmentation (PIH) after 24 weeks of treatment in facial acne participants
Phase:
Phase 4
Details
Lead Sponsor:
Galderma R&D
Treatments:
Trifarotene